Study finds adjuvanted trivalent flu vaccine more effective than standard vaccine in reducing hospitalization in older patients

[www.biospace.com] With the flu season upon us, news about ways to combat the seasonal infectious disease is on the minds of many, particularly those most susceptible. New data released this morning shows there may be a better means of reducing hospitalization risk in older patients.

This morning, Seqirus released new data that shows Fluad, an adjuvanted trivalent influenza vaccine, was more effective than standard non-adjuvanted trivalent influenza vaccine in reducing the risk of flu- and pneumonia-related hospitalization in patients 65-years-of-age and older. Findings from the study, which was led by a team of Brown University researchers, were presented at the National Foundation for Infectious Diseases Clinical Vaccinology Course in Washington, D.C. READ MORE